Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $257,550.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,151 shares of Pro-Dex stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $50.00, for a total transaction of $257,550.00. Following the transaction, the director now directly owns 300,695 shares in the company, valued at approximately $15,034,750. This represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pro-Dex Stock Performance

NASDAQ PDEX traded down $0.77 on Monday, hitting $48.89. 36,103 shares of the stock traded hands, compared to its average volume of 21,554. The business’s fifty day moving average is $39.79 and its two-hundred day moving average is $38.48. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $59.60. The firm has a market capitalization of $159.43 million, a price-to-earnings ratio of 24.32 and a beta of 0.68. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58.

Pro-Dex (NASDAQ:PDEX) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pro-Dex

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Pro-Dex during the fourth quarter valued at approximately $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex during the fourth quarter worth approximately $252,000. Integrated Quantitative Investments LLC bought a new stake in shares of Pro-Dex in the 4th quarter worth approximately $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pro-Dex in the 4th quarter valued at $255,000. Institutional investors own 15.28% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.